Inovio Biomedical received $933,000 from the DoD to advance DNA-based vaccines delivered via its electroporation system. The contract will run through May 2010.
The project focuses on identifying DNA vaccine candidates with the potential to provide rapid, robust immunity to protect against biowarfare and bioterror attacks.
In October 2006, the DoD awarded Inovio $1.1 million to develop its electroporation-based gene delivery technology. The aim was to be able to use this technology in vaccinations against infectious diseases resulting from potential bioterrorism agents.
Inovio president and CEO, Avtar Dhillon, M.D., points out that “knowledge developed from this research is also relevant to the research and development of commercially attractive therapeutic vaccines for targets such as cancer and chronic infectious diseases.”